Human polymorphonuclear neutrophils specifically recognize and kill cancerous cells

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Polymorphonuclear neutrophils (PMNs) are key innate immune effectors.
• PMNs are increasingly recognized for their potential in cancer therapy.
• Previous research indicates possible antitumor effects of PMNs.

Purpose of the Study:

• To investigate the natural anticancer activity of PMNs.
• To determine the specificity of PMN-mediated cancer cell killing.
• To explore the potential of PMNs as an immunotherapy tool.

Main Methods:

• Assessed PMN cytotoxicity against various human cancer cell lines.
• Evaluated PMN interaction with normal epithelial and immortalized breast cell lines.
• Utilized oncogene transfection (Ras, TC21, Rac1) to study PMN targeting mechanisms.
• Compared cancer-killing activity of PMNs from healthy donors and lung cancer patients.

Main Results:

• PMNs from healthy donors exhibited potent, cancer cell-specific killing activity.
• PMNs did not target primary normal epithelial cells or immortalized breast cells.
• Oncogenes Ras and TC21 induced PMN attack, while Rac1 did not, indicating specific targeting.
• PMNs from lung cancer patients showed reduced cancer-killing capacity.

Conclusions:

• PMNs possess inherent cancer-killing capabilities, targeting neoplastic cells specifically.
• PMN-based immunotherapy offers a novel, potentially easily implementable cancer treatment strategy.
• This approach may benefit patients with PMN-vulnerable tumors, representing a paradigm shift in immunotherapy.